Euromed was founded in 1971 as a vertically integrated leading producer of standardised herbal extracts and active pharmaceutical ingredients of botanical origin. Annually, more than 5,000 tonnes of biomass are extracted at two manufacturing plants in Spain, complying with pharmacopoeias and the highest international regulatory standards.
The newest production plant in Murcia further expands Euromed's capabilities with eco-friendly technologies, such as the Pure-Hydro Process, a proprietary ultra-pure water extraction system.
Decades of experience are available to global health ingredients industries seeking consistent standardisation of every production batch, full traceability, identity, purity, safety and evidence-based efficacy.
Innovation and sustainability are also key priorities. In summer 2018 Euromed inaugurated its new Research & Innovation Center in Barcelona, with the objective to bolster its established leading position in producing highest quality botanical extracts, with state-of-the-art technologies and obtained with sustainable agricultural and collection practices.
Commitment to provide evidence-based health benefits is reflected in multiple scientific studies, completed, ongoing and planned, in collaboration with prestigious organisations.
For example, preliminary data from a human study evaluating the efficacy of ABAlife fig extract on glucose metabolism parameters, particularly the Glycemic Index (GI) and the Insulinemic Index (II), were presented at the 78th Annual American Diabetes Association meeting in Orlando, Florida (November 2018) and published on the peer-reviewed journal Diabetes (1). The results of the study, conducted at an Australian University with established expertise in this field, indicate ABAlife efficacy in reducing post-prandial glucose and insulin responses in healthy subjects. The standardised content of abscisic acid (ABA), improves the efficiency of a glucose transporter (Glut 4), therefore ABAlife consumed as a dietary supplement could be an aid in improving glucose tolerance in healthy individuals and those seeking health enhancement.
In 2019 two authoritative academic studies with Euromed flagship fruit extracts Pomanox and Mediteanox were published, both in the peer reviewed open-access journal Nutrients (2,3).
Results from the most recent clinical studies with Pomanox and Mediteanox avail applications as ideal ingredients for cardiovascular health support and sport nutrition.
Pomegranate polyphenols are documented to support endothelial functions and normalize blood pressure (4,5). Several published studies with Pomanox (6-11), administered either in capsules or as a Pomanox-fortified pomegranate juice, confirm a blood pressure lowering effect, besides several other health promoting properties. Consumption of pomegranate juice enriched with Pomanox attenuated exercise-induced oxidative stress (reduction of TBARS), blood pressure and urinary cortisol/cortisone ratio in human volunteers in a published study (10). Now, the sport performance application of Pomanox is further backed by the results of another clinical trial recently published, this time with Pomanox dry extract, in capsules.
The human study, completed by the Health Sciences Department, University of Murcia, Spain, indicates significant post-exercise muscular recovery and force restoration after a prolonged submaximal effort, in twenty-six trained cyclists. The physiological conditions of the physical protocol were similar to those occurring in long-distance competitions, when participants decide to increase their intensity in the last km/miles of the race, after a long submaximal effort and thus Pomanox may be also valuable when our aim is peak performance. The authors conclude that Pomanox, administered for 15 days, may be effective for improving performance outcomes in a maximal effort, and might help to restore force in the damaged muscles, after a prolonged submaximal effort. A strong support for validated applications of this ingredient in nutritional products aimed at safely promoting sport performances and recovery.
A team from the Institute of Health Investigation of La Paz University Hospital, Madrid, Spain, investigated whether combined administration of Hydroxytyrosol (as Mediteanox) and Punicalagin (as Pomanox) versus placebo could exert cardioprotective and anti-atherosclerotic effects. The 20-week cross-over clinical (8 weeks of each treatment) trial on 67 apparently healthy middle-aged subjects, indeed identified significant benefits such as reducing c-LDL (low-density lipoprotein cholesterol) oxidation, improving blood pressure and endothelial functions. The benefits were particularly significant in the subjects with alterations in these atherosclerotic markers. This authoritative study indicates a valuable approach to cardiovascular primary prevention.
1. Zangara A. Diabetes Jul 2018, 67 (Supplement 1) 791-P
2. Quirós-Fernández R, et al. Nutrients 2019, 11, 640
3. Torregrosa-García A, et al. Nutrients 2019, 11, 721
4. Wang D, et al. Front Pharmacol. 2018 May 24; 9:544
5. Sahebkar A, et al. Pharmacol Res. 2017 Jan;115:149-161.
6. Tsang C, et al. J Nutr Sci. (2012), vol. 1, e9:1-9
7. Dujaili AI, et al. Endocrine Abstracts. (2012); 28 P313 10
8. Vilahur G, et al. Rev Esp Cardiol (Engl Ed) (2015) Mar;68(3):216-25
9. Stockton A, et al. EC Nutrition 2.4. (2015): 396-411
10. Dujaili AI, et al. EC Nutrition 4.6 (2016): 982-995
11. Stockton A, et al. J Nutr Sci. (2017); 6: e39
Please use the form below to send us your business enquiry. Thank you!